PROGNOSTIC FACTORS AND OUTCOME IN ASKIN-ROSAI TUMOR: A REVIEW OF 104 PATIENTSLASKAR, Siddhartha; NAIR, Chandrika; MISTRY, Rajesh et al.International journal of radiation oncology, biology, physics. 2011, Vol 79, Num 1, pp 202-207, issn 0360-3016, 6 p.Article

Actualités du 26th Annual San Antonio Breast Cancer Symposium, San Antonio, 3-6 décembre 2003. Compte-renduDIERAS, V; PIERGA, J. Y.La Lettre du cancérologue (Boulogne). 2004, Vol 13, Num 1, issn 1165-113X, 10 p., SUP2Conference Proceedings

2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemiaWEBER, Donna M; DIMOPOULOS, Meletios A; DELASALLE, Kay et al.Seminars in oncology. 2003, Vol 30, Num 2, pp 243-247, issn 0093-7754, 5 p.Article

Nouvelles approches : Mélanome : Système nerveux = New approaches : Melanoma : Nervous systemSAGHATCHIAN-D'ASSIGNIES, M.La Lettre du cancérologue (Boulogne). 2003, Vol 12, Num 3, pp 125-132, issn 1165-113X, 6 p.Article

2003: des progrès majeurs avec les molécules ciblées = 2003: main progress with targeted moleculesMEDIONI, J; KLOOS, I; RAYMOND, E et al.La Lettre du cancérologue (Boulogne). 2003, Vol 12, Num 6, pp 234-238, issn 1165-113X, 5 p.Article

Thérapeutiques moléculaires ciblées en cancérologie bronchique = Target on molecular therapies in lung cancerLE GUEN, Yannick; SABATIER, Laure; LE CHEVALIER, Thierry et al.Bulletin du cancer. 2003, Vol 90, Num 12, pp 1055-1061, issn 0007-4551, 7 p.Article

Hematologic malignancies: New developments and future treatmentsCHESON, Bruce D.Seminars in oncology. 2003, Vol 30, Num 4, pp 33-45, issn 0093-7754, SUP13Article

Targeting HERI/EGFR: A molecular approach to cancer therapyARTEAGA, Carlos.Seminars in oncology. 2003, Vol 30, Num 3, pp 3-14, issn 0093-7754, 12 p., SUP7Article

Rituximab in B-cell chronic lymphocytic leukemiaLIN, Thomas S; LUCAS, Margaret S; BYRD, John C et al.Seminars in oncology. 2003, Vol 30, Num 4, pp 483-492, issn 0093-7754, 10 p.Article

Les inhibiteurs de tyrosine kinase. La cible = Tyrosine kinase inhibitorsMILANO, G.Oncologie (Paris). 2003, Vol 5, Num 7-8, pp 342-344, issn 1292-3818, 3 p.Article

Implications thérapeutiques du récepteur du facteur de croissance épidermique dans le cancer bronchique = Therapeutic implication of EGFR in lung cancerFAYETTE, Jérome; LE CHEVALIER, Thierry; SORIA, Jean-Charles et al.Bulletin du cancer. 2003, Vol 90, Num NOV, pp S233-S240, issn 0007-4551, NSArticle

Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to AP02L/trail-induced apoptosisEVDOKIOU, Andreas; BOURALEXIS, Stelios; ATKINS, Gerald J et al.International journal of cancer. 2002, Vol 99, Num 4, pp 491-504, issn 0020-7136Article

Receptor upregulation enhances cell surface receptor targeted therapiesFRANKEL, Arthur E.Leukemia research. 2002, Vol 26, Num 12, pp 1069-1071, issn 0145-2126, 3 p.Article

Intratumoral cancer chemotherapy and immunotherapy : opportunities for nonsystemic preoperative drug deliveryGOLDBERG, Eugene P; HADBA, Ahmad R; ALMOND, Brett A et al.Journal of pharmacy and pharmacology. 2002, Vol 54, Num 2, pp 159-180, issn 0022-3573Article

Phase I trials of pemetrexedFOSSELLA, Frank V; GATZEMEIER, Ulrich.Seminars in oncology. 2002, Vol 29, Num 2, pp 8-16, issn 0093-7754, SUP5Conference Paper

High-dose therapy and immunomodulatory drugs in multiple myelomaBARLOGIE, Bart; SHAUGHNESSY, John; ZANGARI, Maurizio et al.Seminars in oncology. 2002, Vol 29, Num 6, pp 26-33, issn 0093-7754, 8 p., SUP17Article

Detection of co-expression of EGFRwt with EGFRvIIi in human invasive breast cancerHONG GE; TANG, Careen K.Recent research developments in cancer : Vol. 4 (2002) - Part II. Recent research developments in cancer. 2002, pp 419-427, isbn 81-7895-051-0, 9 p.Book Chapter

Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescueHAGEMEISTER, Fredrick B.Cancer chemotherapy and pharmacology. 2002, Vol 49, pp S13-S20, issn 0344-5704, SUP1Conference Paper

New agents for prostate cancerREESE, David M.Hematology/oncology clinics of North America. 2001, Vol 15, Num 3, issn 0889-8588, vii, 547-557 [12 p.]Article

Oral antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis, and growth factor productionTORTORA, G; BIANCO, R; DAMIANO, V et al.Clinical cancer research. 2000, Vol 6, Num 6, pp 2506-2512, issn 1078-0432Article

Cytokines (IFNs, TNF-α, IL-2 and IL-12) and animal models of cancerBURKE, F.Cytokines, cellular & molecular therapy. 1999, Vol 5, Num 1, pp 51-61, issn 1368-4736Article

Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF : A pharmacokinetic study in advanced sarcoma patientsCERNY, T; LEYVRAZ, S; VON BRIEL, T et al.Annals of oncology. 1999, Vol 10, Num 9, pp 1087-1094, issn 0923-7534Article

Efficacity and pharmacokinetic of all trans retinoic acid (ATRA)/interferon α-2a (INF α-2a) in metastatic renal cell cancerPAULE, B; RUDANT, E; BONHOMME-FAIVRE, L et al.Journal de pharmacie clinique (Paris). 1999, Vol 18, Num 4, pp 318-320, issn 0291-1981Article

Interleukin-12 overcomes paclitaxel-mediated suppression of T-cell proliferationMULLINS, D. W; KOCI, M. D; BURGER, C. J et al.Immunopharmacology and immunotoxicology. 1998, Vol 20, Num 4, pp 473-492, issn 0892-3973Article

New drugs in the treatment of Hodgkin's diseaseBORCHMANN, P; SCHNELL, R; DIEHL, V et al.Annals of oncology. 1998, Vol 9, pp 103-108, issn 0923-7534, SUP5Conference Paper